326 related articles for article (PubMed ID: 23359505)
1. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model.
Sevko A; Michels T; Vrohlings M; Umansky L; Beckhove P; Kato M; Shurin GV; Shurin MR; Umansky V
J Immunol; 2013 Mar; 190(5):2464-71. PubMed ID: 23359505
[TBL] [Abstract][Full Text] [Related]
2. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma.
Sevko A; Sade-Feldman M; Kanterman J; Michels T; Falk CS; Umansky L; Ramacher M; Kato M; Schadendorf D; Baniyash M; Umansky V
J Invest Dermatol; 2013 Jun; 133(6):1610-9. PubMed ID: 23223128
[TBL] [Abstract][Full Text] [Related]
3. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.
Meyer C; Sevko A; Ramacher M; Bazhin AV; Falk CS; Osen W; Borrello I; Kato M; Schadendorf D; Baniyash M; Umansky V
Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17111-6. PubMed ID: 21969559
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-α blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation.
Sade-Feldman M; Kanterman J; Ish-Shalom E; Elnekave M; Horwitz E; Baniyash M
Immunity; 2013 Mar; 38(3):541-54. PubMed ID: 23477736
[TBL] [Abstract][Full Text] [Related]
5. Origin and pharmacological modulation of tumor-associated regulatory dendritic cells.
Zhong H; Gutkin DW; Han B; Ma Y; Keskinov AA; Shurin MR; Shurin GV
Int J Cancer; 2014 Jun; 134(11):2633-45. PubMed ID: 24443321
[TBL] [Abstract][Full Text] [Related]
6. Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation.
Umansky V; Sevko A
Cancer Immunol Immunother; 2012 Feb; 61(2):275-282. PubMed ID: 22120757
[TBL] [Abstract][Full Text] [Related]
7. Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study.
Gebhardt C; Simon SCS; Weber R; Gries M; Mun DH; Reinhard R; Holland-Letz T; Umansky V; Utikal J
Cell Immunol; 2021 Feb; 360():104274. PubMed ID: 33383383
[TBL] [Abstract][Full Text] [Related]
8. Melanoma-induced immunosuppression and its neutralization.
Umansky V; Sevko A
Semin Cancer Biol; 2012 Aug; 22(4):319-26. PubMed ID: 22349515
[TBL] [Abstract][Full Text] [Related]
9. Myeloid-derived suppressor cells in malignant melanoma.
Umansky V; Sevko A; Gebhardt C; Utikal J
J Dtsch Dermatol Ges; 2014 Nov; 12(11):1021-7. PubMed ID: 25263083
[TBL] [Abstract][Full Text] [Related]
10. Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma.
Iannone R; Miele L; Maiolino P; Pinto A; Morello S
Neoplasia; 2013 Dec; 15(12):1400-9. PubMed ID: 24403862
[TBL] [Abstract][Full Text] [Related]
11. CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma.
Umansky V; Blattner C; Gebhardt C; Utikal J
Cancer Immunol Immunother; 2017 Aug; 66(8):1015-1023. PubMed ID: 28382399
[TBL] [Abstract][Full Text] [Related]
12. S100A9 Regulates MDSCs-Mediated Immune Suppression via the RAGE and TLR4 Signaling Pathways in Colorectal Carcinoma.
Huang M; Wu R; Chen L; Peng Q; Li S; Zhang Y; Zhou L; Duan L
Front Immunol; 2019; 10():2243. PubMed ID: 31620141
[TBL] [Abstract][Full Text] [Related]
13. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
Parker KH; Beury DW; Ostrand-Rosenberg S
Adv Cancer Res; 2015; 128():95-139. PubMed ID: 26216631
[TBL] [Abstract][Full Text] [Related]
14. CCR5
Blattner C; Fleming V; Weber R; Himmelhan B; Altevogt P; Gebhardt C; Schulze TJ; Razon H; Hawila E; Wildbaum G; Utikal J; Karin N; Umansky V
Cancer Res; 2018 Jan; 78(1):157-167. PubMed ID: 29089297
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic melanoma inhibition by local micelle-mediated cyclic nucleotide repression.
Johann K; Bohn T; Shahneh F; Luther N; Birke A; Jaurich H; Helm M; Klein M; Raker VK; Bopp T; Barz M; Becker C
Nat Commun; 2021 Oct; 12(1):5981. PubMed ID: 34645812
[TBL] [Abstract][Full Text] [Related]
16. Differential response of myeloid-derived suppressor cells to the nonsteroidal anti-inflammatory agent indomethacin in tumor-associated and tumor-free microenvironments.
Blidner AG; Salatino M; Mascanfroni ID; Diament MJ; Bal de Kier Joffé E; Jasnis MA; Klein SM; Rabinovich GA
J Immunol; 2015 Apr; 194(7):3452-62. PubMed ID: 25740944
[TBL] [Abstract][Full Text] [Related]
17. Disrupted lymph node and splenic stroma in mice with induced inflammatory melanomas is associated with impaired recruitment of T and dendritic cells.
Soudja SM; Henri S; Mello M; Chasson L; Mas A; Wehbe M; Auphan-Anezin N; Leserman L; Van den Eynde B; Schmitt-Verhulst AM
PLoS One; 2011; 6(7):e22639. PubMed ID: 21811640
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner.
Michels T; Shurin GV; Naiditch H; Sevko A; Umansky V; Shurin MR
J Immunotoxicol; 2012; 9(3):292-300. PubMed ID: 22283566
[TBL] [Abstract][Full Text] [Related]
19. Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions.
Zhou J; Wu J; Chen X; Fortenbery N; Eksioglu E; Kodumudi KN; Pk EB; Dong J; Djeu JY; Wei S
Int Immunopharmacol; 2011 Jul; 11(7):890-8. PubMed ID: 21244860
[TBL] [Abstract][Full Text] [Related]
20. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.
Lesokhin AM; Hohl TM; Kitano S; Cortez C; Hirschhorn-Cymerman D; Avogadri F; Rizzuto GA; Lazarus JJ; Pamer EG; Houghton AN; Merghoub T; Wolchok JD
Cancer Res; 2012 Feb; 72(4):876-86. PubMed ID: 22174368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
